OSE Immunotherapeutics S.A.
OSE.PA · PAR
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | €69,877 | €2,227 | €18,302 | €26,306 |
| % Growth | 3,037.7% | -87.8% | -30.4% | – |
| Cost of Goods Sold | €0 | €0 | €0 | €0 |
| Gross Profit | €69,877 | €2,227 | €18,302 | €26,306 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | €32,855 | €17,158 | €26,893 | €30,550 |
| G&A Expenses | €6,260 | €5,962 | €6,594 | €8,503 |
| SG&A Expenses | €8,664 | €7,996 | €9,724 | €12,276 |
| Sales & Mktg Exp. | €2,724 | €2,034 | €3,130 | €3,773 |
| Other Operating Expenses | €0 | €59 | €161 | €105 |
| Operating Expenses | €41,519 | €25,213 | €36,778 | €42,931 |
| Operating Income | €43,735 | -€22,986 | -€18,476 | -€16,625 |
| % Margin | 62.6% | -1,032.2% | -101% | -63.2% |
| Other Income/Exp. Net | -€3,903 | -€235 | €454 | -€588 |
| Pre-Tax Income | €39,832 | -€23,222 | -€23,454 | -€21,558 |
| Tax Expense | €2,387 | -€219 | -€5,694 | -€4,708 |
| Net Income | €37,445 | -€23,003 | -€17,760 | -€16,850 |
| % Margin | 53.6% | -1,032.9% | -97% | -64.1% |
| EPS | 1.72 | -1.18 | -0.96 | -0.93 |
| % Growth | 245.8% | -22.9% | -3.2% | – |
| EPS Diluted | 1.72 | -1.18 | -0.96 | -0.93 |
| Weighted Avg Shares Out | 21,808 | 19,562 | 18,457 | 18,155 |
| Weighted Avg Shares Out Dil | 21,808 | 19,562 | 18,457 | 18,155 |
| Supplemental Information | – | – | – | – |
| Interest Income | €1,467 | €335 | €15 | €7 |
| Interest Expense | €3,302 | €2,269 | €1,372 | €836 |
| Depreciation & Amortization | €3,363 | €3,525 | €3,557 | €2,657 |
| EBITDA | €41,195 | -€17,501 | -€13,113 | -€13,720 |
| % Margin | 59% | -785.9% | -71.6% | -52.2% |